Revised SPC: Zyban (buproprion) 150 mg prolonged release tablets

SPC warns of risk of serotonin syndrome when co-administered with selective serotonin reuptake inhibitors/serotonin norepinephrine re-uptake inhibitors. If concomitant treatment is required, careful observation is advised, particularly during treatment initiation/dose increases.

Source:

electronic Medicines compendium